scholarly journals Radioiodine Treatment of Differentiated Thyroid Cancer at CNMU, Rajshahi

1970 ◽  
Vol 16 (2) ◽  
pp. 54-57
Author(s):  
MM Ahasan ◽  
FU Ahmed ◽  
SM Bodrudozza ◽  
SMK Hasan ◽  
MN Khanam
Keyword(s):  
Thyroid Cancer ◽  
Single Dose ◽  
Retrospective Study ◽  
Differentiated Thyroid Cancer ◽  
Age Group ◽  
Radioiodine Treatment ◽  
Residual Tissue

A retrospective study has been conducted on 19 patients who attended at CNMU, Rajshahi withdifferentiated thyroid cancer, treated with radioiodine for ablation of residual tissue afterthyroidectomy. The patients included in this study were between 06 to 70 years of age, the meanage being about 36 years. The main objective of the study was to evaluate the response of theradioiodine therapy in patient with differentiated thyroid cancer after surgery. The incidence ofpapillary, follicular and mixed variety was found in approximately 69%, 26% and 5% casesrespectively. Result showed that the incidence of thyroid cancer were found more,approximately 58% in the age group 21-40 years. Results also showed that papillary carcinomainvolved approximately 23% in male and 77% in female. It was also found that approximately89% patients were treated successfully by single dose of radioiodine.doi: 10.3329/taj.v16i2.3882TAJ December 2003; Vol.16(2): 54-57

scholarly journals Assessment of Gonadal Function Following Single Dose of Radioiodine Therapy in Differentiated Thyroid Cancer Patients of Reproductive Age

2018 ◽  
Vol 19 (2) ◽  
pp. 92
Author(s):  
Md Sunny Anam Chowdhury ◽  
Sadia Sultana ◽  
Md Abdul Awal ◽  
Suraya Sarmin ◽  
Mohammad Simoon Salekin
Keyword(s):  
Thyroid Cancer ◽  
Single Dose ◽  
Differentiated Thyroid Cancer ◽  
Reproductive Age ◽  
Age Group ◽  
Gonadal Function ◽  
Male Patients ◽  
The Mean ◽  
Reproductive Age Group

<p><strong>Objective</strong>: This interventional study has undertaken to assess the gonadal function of differentiated thyroid cancer (DTC) patients within reproductive age group following single dose of radioactive iodine (131I) therapy/ablation.</p><p><strong>Patients and Methods:<em> </em></strong>A total of 69 patients (25 male and 44 female) of DTC were included in this study, those were referred for 131I ablation after total thyroidectomy. Following RAI, these patients were followed-up three times at three months interval.  The usual I-131 dose was 75 or 100 m Ci for ablation of thyroid residues and 150 mCi for treatment of nodal metastasis. All the patients were interviewed about menstrual (female only) and reproductive history and investigated of the level of follicle stimulating hormone (FSH), luteinizing hormone (LH), testosterone of male patients and FSH, LH, estradiol (E<sub>2</sub>) of female patients before administration of  131I and three, six and nine months after therapy.</p><p><strong>Result</strong>: In this study all of the 25 (100.0%) male patients showed high FSH level after three months of therapy. The mean± SD FSH level of male patients was found significantly (p-0.001) higher (15.59±7.53 IU/L) after three months of therapy than the pretherapy (4.85±2.57 IU/L) level.  The mean± SD of FSH level was significantly declining in six months and nine months of follow up. The mean± SD of LH hormone level of these patients was found 6.1±3.67 IU/L in pretherapy which was significantly increased to 7.67±4.33 IU/L after three months. The mean LH level was 7.20±3.98 IU/L at six months follow up and 7.3±3.5IU/L after nine months. The differences of LH level between 3 months to 6 months and 6 months to 9 months are not statistically significant. No significant change was observed in testosterone level throughout the study period. In female, five patients developed irregular menstruation (changed duration of cycle or lighter amount), three patients developed amenorrhea associated with hot flashes within six months of 131I administration. Biochemical study of the patients with amenorrhoea showed markedly elevated serum FSH, LH level and declined E<sub>2 </sub>level. The FSH, LH levels of the two patients with amenorrhea became normal within study period and one patient had persistent amenorrhea at 9 months. E<sub>2</sub> level raised slowly.</p><p><strong>Conclusion</strong>: A single dose of radio-iodine (131I) therapy causes impairment of gonadal function of male patients within reproductive age group. In case of female patients the effect is insignificant. The effect is usually reversible and gonadal function of the patients restores within the study period.</p><p>Bangladesh J. Nuclear Med. 19(2): 92-97, July 2016  </p>

scholarly journals Extended single-dose toxicity study of [211At]NaAt in mice for the first-in-human clinical trial of targeted alpha therapy for differentiated thyroid cancer

2021 ◽  
Author(s):  
Tadashi Watabe ◽  
Kazuko Kaneda-Nakashima ◽  
Kazuhiro Ooe ◽  
Yuwei Liu ◽  
Kenta Kurimoto ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Body Weight ◽  
Thyroid Cancer ◽  
Single Dose ◽  
General Condition ◽  
Blood Test ◽  
Differentiated Thyroid Cancer ◽  
Targeted Alpha Therapy ◽  
Evaluation Point ◽  
Alpha Therapy

Abstract Objective Astatine (211At) is a promising alpha emitter as an alternative to iodine (131I). We are preparing the first-in-human (FIH) clinical trial of targeted alpha therapy for differentiated thyroid cancer in consultation with Pharmaceuticals and Medical Devices Agency. Here, we performed an extended single-dose toxicity examination under a reliability standard, as a preclinical safety assessment of [211At]NaAt to determine the FIH dose. Methods [211At]NaAt solution was injected into normal 6-week-old mice (male (n = 50) and female (n = 50), body weight: male 33.2 ± 1.7 g, female 27.3 ± 1.5 g), which were then divided into four groups: 5 MBq/kg (n = 20), 20 MBq/kg (n = 20), 50 MBq/kg (n = 30), saline control (n = 30). The mice were followed up for 5 days (primary evaluation point for acute toxicity: n = 80) or 14 days (n = 20: evaluation point for recovery) to monitor general condition and body weight change. At the end of the observation period, necropsy, blood test, organ weight measurement, and histopathological examination were performed. For body weight, blood test, and organ weight, statistical analyses were performed to compare data between the control and injected groups. Results No abnormal findings were observed in the general condition of mice. In the 50 MBq/kg group, males (days 3 and 5) showed a significant decrease in body weight compared with the control. However, necropsy did not differ significantly beyond the range of spontaneous lesions. In the blood test, males (50 MBq/kg) and females (50 MBq/kg) showed a decrease in white blood cell and platelet counts on day 5, and recovery on day 14. In the testis, a considerable weight decrease was observed on day 14 (50 MBq/kg), and multinucleated giant cells were observed in all mice, indicating a significant change related to the administration of [211At]NaAt. Conclusions In the extended single-dose toxicity study of [211At]NaAt, administration of high doses resulted in weight loss, transient bone marrow suppression, and pathological changes in the testis, which require consideration in the FIH clinical trial.

Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study.

1998 ◽  
Vol 16 (11) ◽  
pp. 3542-3549 ◽  
Author(s):  
K H Bohuslavizki ◽  
S Klutmann ◽  
W Brenner ◽  
J Mester ◽  
E Henze ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Salivary Gland ◽  
Salivary Glands ◽  
Differentiated Thyroid Cancer ◽  
Controlled Study ◽  
High Dose ◽  
Radioiodine Treatment ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Submandibular Glands

PURPOSE Salivary gland impairment is a well-recognized side effect following high-dose radioiodine treatment (HD-RIT). Since differentiated thyroid cancer has a good prognosis, reduction of long-term side effects is important. Therefore, the effect of amifostine was studied in HD-RIT. PATIENTS AND METHODS Parenchymal function was assessed by quantitative salivary gland scintigraphy performed prospectively in 50 patients with differentiated thyroid cancer before and 3 months after HD-RIT with either 3 GBq iodine ((131)I) (n=21) or 6 GBq (131)I (n=29) in a double-blind, placebo-controlled study. Twenty-five patients were treated with 500 mg/m2 amifostine intravenously before HD-RIT and 25 patients served as controls, who received physiologic saline solution. Xerostomia was graded according to World Health Organization (WHO) criteria. RESULTS Before HD-RIT in 25 control patients, uptake of technetium-99m (99mTc)-pertechnetate was 0.45%+/-0.16% and 0.42%+/-0.16% in parotid and submandibular glands, respectively. Three months after HD-RIT, parenchymal function was significantly (P < .001) reduced by 40.2%+/-14.1% and 39.9%+/-15.3% in parotid and submandibular glands, respectively. Nine control patients developed grade I and two grade II xerostomia. In 25 amifostine-treated patients, uptake of 99mTc-pertechnetate was 0.46%+/-0.16% and 0.43%+/-0.17% in parotid and submandibular glands, respectively. Three months after HD-RIT, parenchymal function of salivary glands was not significantly altered (P=.691) and xerostomia did not occur in any of these patients. CONCLUSION Parenchymal damage in salivary glands caused by HD-RIT can significantly be reduced by amifostine, which may improve the quality of life of patients with differentiated thyroid cancer.

Sign in / Sign up

Export Citation Format

Share Document